Theranos Sham Blood-Testing Fraud (2003–2022)
Introduction
Theranos was a Silicon Valley blood-testing startup founded by 19-year-old Stanford dropout Elizabeth Holmes in 2003. Its central claim was that a proprietary device — the Edison — could run hundreds of standard laboratory tests from a single finger-prick of blood, faster and cheaper than conventional laboratory methods. The company raised more than $900 million from investors, reached a peak valuation of $9 billion, and was named one of America''s most innovative companies. The technology never worked as claimed.
The Fraud
Internal Theranos documents produced in litigation and reported by Wall Street Journal investigative journalist John Carreyrou (beginning October 2015) showed that the Edison device could reliably perform only a handful of tests — not the hundreds advertised. For most of its test menu, Theranos was using conventional third-party laboratory equipment (Siemens, for example) while presenting results to patients as if they came from the Edison. Results from the Edison were frequently inaccurate, and Theranos had internal evidence of this.
Theranos operated patient service centres inside Walgreens pharmacy locations in Arizona and California, providing test results to real patients who then used those results to make health decisions. The company knew its validation data was inadequate and that the Edison''s accuracy was not comparable to certified laboratory standards.
Patient Impact
In 2016, Theranos notified approximately 176,000 patients that their Edison-generated test results from 2014–2015 were being voided because the company could no longer stand behind their accuracy. Some of those patients had made clinical decisions — including decisions about medication, surgery, and disease management — based on the voided results. The full patient impact has been difficult to quantify because Theranos did not systematically track downstream clinical consequences.
The Centers for Medicare and Medicaid Services (CMS) conducted an inspection of the Theranos Newark, California laboratory in 2015–2016 and found it posed "immediate jeopardy" to patient health. CMS revoked Theranos''s CLIA laboratory certification and banned Holmes personally from operating a laboratory for two years.
Criminal Convictions
Elizabeth Holmes was indicted in 2018 on federal wire fraud and conspiracy charges. After a lengthy trial, she was convicted in January 2022 on four counts of wire fraud against investors and sentenced to 11 years and three months in federal prison. She began serving her sentence in 2023.
Ramesh "Sunny" Balwani, Theranos''s president and COO (and Holmes''s romantic partner during the fraud period), was tried separately and convicted in July 2022 on all 12 counts — including wire fraud against patients as well as investors. He was sentenced to nearly 13 years in federal prison.
The Carreyrou Investigation
John Carreyrou''s October 2015 Wall Street Journal article, "Hot Startup Theranos Has Struggled With Its Blood-Test Technology," was the first public exposure of the fraud. Carreyrou subsequently published the definitive account, Bad Blood: Secrets and Lies in a Silicon Valley Startup (2018), which drew on whistleblower sources including former employees Tyler Shultz and Erika Cheung. Theranos attempted to use legal threats to silence sources and Carreyrou; the efforts failed.
Verdict
Confirmed. Federal criminal convictions of Holmes (4 counts, 11 years) and Balwani (12 counts, 13 years) confirm the fraudulent nature of Theranos''s claims. Approximately 176,000 patients received voided test results. CMS found immediate jeopardy to patient health. The fraud was sustained across more than a decade and deceived investors, partners, regulators, and patients.
Evidence Filters19
176,000 patient test results voided (2016)
SupportingStrongTheranos notified approximately 176,000 patients in 2016 that their Edison-generated test results from 2014–2015 were being voided because the company could no longer stand behind their accuracy. Some of those patients had made clinical decisions based on those results.
Holmes convicted: 4 counts wire fraud, 11 years (January 2022)
SupportingStrongElizabeth Holmes was convicted in January 2022 on four counts of wire fraud against investors and sentenced to 11 years and 3 months in federal prison. The conviction followed a full jury trial with extensive documentary and whistleblower evidence.
Balwani convicted: 12 counts, nearly 13 years (July 2022)
SupportingStrongRamesh Balwani was convicted in July 2022 on all 12 counts, including wire fraud against both investors and patients. His sentence of nearly 13 years exceeded Holmes's, reflecting the jury's finding of broader culpability.
CMS: "immediate jeopardy" to patient health, CLIA revoked
SupportingStrongThe Centers for Medicare and Medicaid Services inspected Theranos's Newark laboratory in 2015–2016, found it posed immediate jeopardy to patient health, and revoked its CLIA laboratory certification. Holmes was personally banned from operating a laboratory for two years.
Edison device validated only a handful of tests, not hundreds
SupportingStrongInternal documents and testimony showed the Edison could reliably perform only a small fraction of the tests Theranos advertised. For most of its menu, Theranos used conventional third-party laboratory equipment — Siemens and others — while presenting results as Edison-derived.
Whistleblowers Tyler Shultz and Erika Cheung provided documented evidence
SupportingStrongFormer Theranos employees Tyler Shultz (grandson of board member George Shultz) and Erika Cheung provided detailed whistleblower testimony and documentation to regulators and journalists. Their accounts are corroborated by internal documents produced in litigation.
Theranos used legal threats to suppress early whistleblowers
SupportingTheranos employed its general counsel and outside law firm to threaten former employees with litigation for breach of non-disclosure agreements. The suppression of internal dissent delayed public exposure of the fraud by months or years.
Board included distinguished figures who provided credibility cover
DebunkingWeakTheranos's board included former Secretaries of State George Shultz and Henry Kissinger, former Secretary of Defense James Mattis, and other prominent figures who provided reputational cover but had no relevant scientific or medical expertise. Their presence does not exculpate Holmes but illustrates how institutional credibility was leveraged.
Rebuttal
High-profile board membership is not exculpatory; it was itself part of the fraud strategy. The presence of distinguished non-scientists on the board does not alter the fraudulent nature of the underlying technology claims.
Internal Proficiency Testing Results Showed Systemic Inaccuracy
SupportingStrongDocuments entered at Holmes' federal trial showed Theranos's own internal quality control data revealed Edison device results for HIV, HbA1c, and sodium tests routinely fell outside acceptable accuracy ranges. The company suppressed this data while publicly claiming FDA-comparable precision.
Whistleblower Tyler Shultz Corroborated Erika Cheung's Testimony
SupportingStrongTwo separate Theranos employees, Tyler Shultz (grandson of board member George Shultz) and Erika Cheung, independently contacted the CMS and Wall Street Journal with consistent accounts of altered quality controls, manipulated test samples, and threatened employees. Their corroborating testimony was central to the criminal case.
Show 9 more evidence points
Holmes Argued She Genuinely Believed Technology Was Viable
DebunkingHolmes' defence at trial maintained she was a true believer who made optimistic projections in good faith and was partly misled by laboratory director Ramesh Balwani. The jury acquitted her on four charges related to investor fraud and charges involving patients, suggesting some evidence for genuine rather than purely cynical deception.
Some Early Theranos Technology Produced Valid Results for Limited Assay Types
NeutralTheranos's proprietary "Edison" devices, while demonstrably incapable of the broad testing menu the company claimed, did produce clinically valid results for a narrow range of assays — notably certain finger-stick tests for influenza antigens. CMS inspection reports and trial evidence distinguished between tests run on Theranos proprietary hardware (unreliable for most analytes) and tests the company ran on modified third-party Siemens and other commercial analyzers (more reliable). The company's fraud was in representing proprietary technology as universally validated when it was not, and in using third-party equipment while claiming proprietary results. This is criminal fraud, but it coexisted with partial genuine technical capability, complicating all-or-nothing "fake technology" characterizations.
Investor Due-Diligence Failure Is a Distinct Issue From Criminal Fraud
NeutralMajor Theranos investors — including Rupert Murdoch, the DeVos family, and Walgreens — failed to conduct standard scientific due diligence before committing hundreds of millions of dollars. Standard venture-practice peer review of Theranos's technology claims was not performed, partly because Holmes leveraged board prestige and NDAs to prevent it. This investor failure does not diminish Holmes's criminal culpability, which courts affirmed, but it raises questions about why sophisticated investors accepted claims without verification. The fraud narrative is accurate; however, the additional framing of Theranos as an elaborate conspiracy that fooled rigorous scrutiny is inaccurate — scrutiny was largely absent by choice of the investors involved.
Some Early Theranos Influenza Assays Functioned Adequately for Limited Diagnostic Purposes
NeutralTheranos's FDA submission for a herpes simplex virus-1 test received clearance in 2015, and internal documents show some influenza and other assays performed within acceptable ranges on standard Siemens and other third-party analyzers Theranos used. The core fraud involved claiming proprietary Edison device capability that did not exist, not that zero tests worked. Distinguishing between the categories of test performance — some assays functional, many not, Edison platform uniformly inadequate — matters for understanding the specific fraud rather than treating the technology as entirely fictional from inception.
Investor Due-Diligence Failure Is Analytically Separable from Holmes's Criminal Fraud
NeutralTheranos's investor base included Rupert Murdoch, Betsy DeVos, and the Walton family — sophisticated principals who invested without requiring standard venture due diligence, including independent technical validation or audited financials. Holmes's ability to maintain deception partly depended on investors' willingness to accept secrecy as a sign of competitive sensitivity rather than a red flag. The criminal fraud finding rightly rests on Holmes's misrepresentations; the scale of capital raised reflects a failure of investor discipline that was self-inflicted, not solely Holmes's creation. Both are true simultaneously.
Some Early Theranos Technology Produced Valid Results in Limited Range
NeutralTheranos's miniLab platform showed genuine developmental promise for a small subset of tests — particularly herpes simplex and influenza immunoassays using modified Siemens ADVIA platforms. FDA cleared one Theranos test (Zika virus, 2016) under emergency use. This partial technical validity does not excuse the fraudulent clinical claims but complicates a narrative of pure invention-from-nothing. Investor and partner due-diligence failures — Walgreens sent no clinical staff to evaluate the technology — are separable from Holmes's criminal fraud culpability.
Holmes's Conviction Scope Was Narrower Than Public Narrative
DebunkingHolmes was acquitted on four of eleven counts, including all charges related to patient fraud, and convicted only on investor-fraud counts. The jury's split verdict suggests the evidence supported a more bounded conspiracy than the "wholesale patient endangerment by design" framing in popular accounts. This does not mitigate the harm to patients who received inaccurate results, but it means attributing to Holmes a fully coordinated conspiracy to endanger patients specifically — rather than to defraud investors — overstates what the trial record established.
Some Early Theranos Technology Produced Commercially Viable Results for Specific Tests
NeutralIndependent analysis, including reporting from the AACC and some former Theranos scientists, acknowledged that the company's conventional laboratory analyzers — as opposed to the Edison devices — produced results within normal accuracy ranges for a subset of standard tests. The fraud centered on misrepresenting the Edison device's capabilities and using conventional Siemens analyzers while claiming proprietary nano-technology. The distinction matters: investor deception about which technology was producing results is different from every test result being fabricated.
Sophisticated Investor Due-Diligence Failure Was Separable From Holmes's Criminal Conduct
NeutralTheranos's board included former secretaries of state, defense secretaries, and senior military figures — sophisticated parties with access to technical advisors. The failure of these investors to demand independent validation of the technology before committing capital reflects a due-diligence failure on their part, not solely Holmes's deception. The criminal conviction addressed Holmes's specific misrepresentations to investors and patients, not a broader finding that all losses were solely attributable to fraud rather than investor negligence.
Evidence Cited by Believers9
176,000 patient test results voided (2016)
SupportingStrongTheranos notified approximately 176,000 patients in 2016 that their Edison-generated test results from 2014–2015 were being voided because the company could no longer stand behind their accuracy. Some of those patients had made clinical decisions based on those results.
Holmes convicted: 4 counts wire fraud, 11 years (January 2022)
SupportingStrongElizabeth Holmes was convicted in January 2022 on four counts of wire fraud against investors and sentenced to 11 years and 3 months in federal prison. The conviction followed a full jury trial with extensive documentary and whistleblower evidence.
Balwani convicted: 12 counts, nearly 13 years (July 2022)
SupportingStrongRamesh Balwani was convicted in July 2022 on all 12 counts, including wire fraud against both investors and patients. His sentence of nearly 13 years exceeded Holmes's, reflecting the jury's finding of broader culpability.
CMS: "immediate jeopardy" to patient health, CLIA revoked
SupportingStrongThe Centers for Medicare and Medicaid Services inspected Theranos's Newark laboratory in 2015–2016, found it posed immediate jeopardy to patient health, and revoked its CLIA laboratory certification. Holmes was personally banned from operating a laboratory for two years.
Edison device validated only a handful of tests, not hundreds
SupportingStrongInternal documents and testimony showed the Edison could reliably perform only a small fraction of the tests Theranos advertised. For most of its menu, Theranos used conventional third-party laboratory equipment — Siemens and others — while presenting results as Edison-derived.
Whistleblowers Tyler Shultz and Erika Cheung provided documented evidence
SupportingStrongFormer Theranos employees Tyler Shultz (grandson of board member George Shultz) and Erika Cheung provided detailed whistleblower testimony and documentation to regulators and journalists. Their accounts are corroborated by internal documents produced in litigation.
Theranos used legal threats to suppress early whistleblowers
SupportingTheranos employed its general counsel and outside law firm to threaten former employees with litigation for breach of non-disclosure agreements. The suppression of internal dissent delayed public exposure of the fraud by months or years.
Internal Proficiency Testing Results Showed Systemic Inaccuracy
SupportingStrongDocuments entered at Holmes' federal trial showed Theranos's own internal quality control data revealed Edison device results for HIV, HbA1c, and sodium tests routinely fell outside acceptable accuracy ranges. The company suppressed this data while publicly claiming FDA-comparable precision.
Whistleblower Tyler Shultz Corroborated Erika Cheung's Testimony
SupportingStrongTwo separate Theranos employees, Tyler Shultz (grandson of board member George Shultz) and Erika Cheung, independently contacted the CMS and Wall Street Journal with consistent accounts of altered quality controls, manipulated test samples, and threatened employees. Their corroborating testimony was central to the criminal case.
Counter-Evidence3
Board included distinguished figures who provided credibility cover
DebunkingWeakTheranos's board included former Secretaries of State George Shultz and Henry Kissinger, former Secretary of Defense James Mattis, and other prominent figures who provided reputational cover but had no relevant scientific or medical expertise. Their presence does not exculpate Holmes but illustrates how institutional credibility was leveraged.
Rebuttal
High-profile board membership is not exculpatory; it was itself part of the fraud strategy. The presence of distinguished non-scientists on the board does not alter the fraudulent nature of the underlying technology claims.
Holmes Argued She Genuinely Believed Technology Was Viable
DebunkingHolmes' defence at trial maintained she was a true believer who made optimistic projections in good faith and was partly misled by laboratory director Ramesh Balwani. The jury acquitted her on four charges related to investor fraud and charges involving patients, suggesting some evidence for genuine rather than purely cynical deception.
Holmes's Conviction Scope Was Narrower Than Public Narrative
DebunkingHolmes was acquitted on four of eleven counts, including all charges related to patient fraud, and convicted only on investor-fraud counts. The jury's split verdict suggests the evidence supported a more bounded conspiracy than the "wholesale patient endangerment by design" framing in popular accounts. This does not mitigate the harm to patients who received inaccurate results, but it means attributing to Holmes a fully coordinated conspiracy to endanger patients specifically — rather than to defraud investors — overstates what the trial record established.
Neutral / Ambiguous7
Some Early Theranos Technology Produced Valid Results for Limited Assay Types
NeutralTheranos's proprietary "Edison" devices, while demonstrably incapable of the broad testing menu the company claimed, did produce clinically valid results for a narrow range of assays — notably certain finger-stick tests for influenza antigens. CMS inspection reports and trial evidence distinguished between tests run on Theranos proprietary hardware (unreliable for most analytes) and tests the company ran on modified third-party Siemens and other commercial analyzers (more reliable). The company's fraud was in representing proprietary technology as universally validated when it was not, and in using third-party equipment while claiming proprietary results. This is criminal fraud, but it coexisted with partial genuine technical capability, complicating all-or-nothing "fake technology" characterizations.
Investor Due-Diligence Failure Is a Distinct Issue From Criminal Fraud
NeutralMajor Theranos investors — including Rupert Murdoch, the DeVos family, and Walgreens — failed to conduct standard scientific due diligence before committing hundreds of millions of dollars. Standard venture-practice peer review of Theranos's technology claims was not performed, partly because Holmes leveraged board prestige and NDAs to prevent it. This investor failure does not diminish Holmes's criminal culpability, which courts affirmed, but it raises questions about why sophisticated investors accepted claims without verification. The fraud narrative is accurate; however, the additional framing of Theranos as an elaborate conspiracy that fooled rigorous scrutiny is inaccurate — scrutiny was largely absent by choice of the investors involved.
Some Early Theranos Influenza Assays Functioned Adequately for Limited Diagnostic Purposes
NeutralTheranos's FDA submission for a herpes simplex virus-1 test received clearance in 2015, and internal documents show some influenza and other assays performed within acceptable ranges on standard Siemens and other third-party analyzers Theranos used. The core fraud involved claiming proprietary Edison device capability that did not exist, not that zero tests worked. Distinguishing between the categories of test performance — some assays functional, many not, Edison platform uniformly inadequate — matters for understanding the specific fraud rather than treating the technology as entirely fictional from inception.
Investor Due-Diligence Failure Is Analytically Separable from Holmes's Criminal Fraud
NeutralTheranos's investor base included Rupert Murdoch, Betsy DeVos, and the Walton family — sophisticated principals who invested without requiring standard venture due diligence, including independent technical validation or audited financials. Holmes's ability to maintain deception partly depended on investors' willingness to accept secrecy as a sign of competitive sensitivity rather than a red flag. The criminal fraud finding rightly rests on Holmes's misrepresentations; the scale of capital raised reflects a failure of investor discipline that was self-inflicted, not solely Holmes's creation. Both are true simultaneously.
Some Early Theranos Technology Produced Valid Results in Limited Range
NeutralTheranos's miniLab platform showed genuine developmental promise for a small subset of tests — particularly herpes simplex and influenza immunoassays using modified Siemens ADVIA platforms. FDA cleared one Theranos test (Zika virus, 2016) under emergency use. This partial technical validity does not excuse the fraudulent clinical claims but complicates a narrative of pure invention-from-nothing. Investor and partner due-diligence failures — Walgreens sent no clinical staff to evaluate the technology — are separable from Holmes's criminal fraud culpability.
Some Early Theranos Technology Produced Commercially Viable Results for Specific Tests
NeutralIndependent analysis, including reporting from the AACC and some former Theranos scientists, acknowledged that the company's conventional laboratory analyzers — as opposed to the Edison devices — produced results within normal accuracy ranges for a subset of standard tests. The fraud centered on misrepresenting the Edison device's capabilities and using conventional Siemens analyzers while claiming proprietary nano-technology. The distinction matters: investor deception about which technology was producing results is different from every test result being fabricated.
Sophisticated Investor Due-Diligence Failure Was Separable From Holmes's Criminal Conduct
NeutralTheranos's board included former secretaries of state, defense secretaries, and senior military figures — sophisticated parties with access to technical advisors. The failure of these investors to demand independent validation of the technology before committing capital reflects a due-diligence failure on their part, not solely Holmes's deception. The criminal conviction addressed Holmes's specific misrepresentations to investors and patients, not a broader finding that all losses were solely attributable to fraud rather than investor negligence.
Timeline
Wall Street Journal publishes Carreyrou investigation
John Carreyrou's WSJ article reveals Theranos relies on conventional equipment for most tests and that Edison accuracy is inadequate. Theranos responds with aggressive legal threats and public denials. The FDA begins inspections.
Source →CMS Bans Holmes from Operating Clinical Labs for Two Years
The Centers for Medicare and Medicaid Services issued findings from its Newark, California laboratory inspection citing immediate jeopardy to patient health and safety. CMS subsequently banned Elizabeth Holmes personally from operating or directing any clinical laboratory for two years — an extraordinary enforcement action rarely applied to an individual CEO.
Source →CMS revokes CLIA certification; Holmes banned from lab operations
CMS finds the Theranos Newark laboratory poses "immediate jeopardy" to patient health and revokes its CLIA certification. Holmes is personally barred from operating a laboratory for two years. Theranos begins voiding two years of patient test results.
Holmes convicted: 4 counts wire fraud, sentenced to 11 years
After a lengthy federal trial with extensive documentary and whistleblower evidence, Elizabeth Holmes is convicted of four counts of wire fraud against investors. She is sentenced to 11 years and 3 months in federal prison. Balwani is tried separately.
Source →
Verdict
Federal criminal convictions confirm the fraud: Holmes convicted of four counts of wire fraud (January 2022, 11 years); Balwani convicted of 12 counts (July 2022, nearly 13 years). Theranos voided approximately 176,000 patient test results in 2016. CMS found "immediate jeopardy" to patient health. The company raised $900M on claims its Edison device could not substantiate. John Carreyrou's 2015 WSJ investigation and subsequent book Bad Blood provide the definitive journalistic record.
Frequently Asked Questions
What exactly did the Theranos Edison device fail to do?
The Edison was claimed to run hundreds of standard laboratory tests from a single finger-prick of blood. In practice it could reliably perform only a small fraction of those tests. Theranos used conventional laboratory equipment from manufacturers like Siemens for most of its menu, presenting results to patients as if they came from the Edison. The Edison's accuracy on the tests it did attempt was not equivalent to certified laboratory standards.
Were patients harmed?
Approximately 176,000 patients received voided test results in 2016. Some of those patients had made clinical decisions — including decisions about medication, surgery, and disease management — based on results Theranos later acknowledged were unreliable. The full patient harm is difficult to quantify because Theranos did not systematically track downstream clinical consequences.
Why wasn't the fraud detected sooner?
Theranos operated with extreme secrecy, citing trade secret protection to avoid standard laboratory validation processes. Its board of distinguished non-scientists provided reputational cover. The company used legal threats to silence early whistleblowers. Regulatory oversight of laboratory-developed tests in this period was limited. The WSJ investigation broke the story after Carreyrou cultivated whistleblower sources over many months.
What happened to Elizabeth Holmes and Sunny Balwani?
Sources
Show 6 more sources
Further Reading
- bookBad Blood: Secrets and Lies in a Silicon Valley Startup — John Carreyrou (2018)
- documentaryThe Dropout (Hulu documentary series) — Elizabeth Meriwether (2022)
- paperUS v. Holmes — trial transcript and jury instructions — US District Court N.D. California (2022)
- podcastThe Dropout — Audio Documentary Podcast Series — Rebecca Jarvis (2019)